Related Experiment Video
Updated: Jun 15, 2026
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Emerging drugs for chronic myeloid leukemia
Daniela Cilloni1, Emanuela Messa, Antonia Rotolo
1University of Turin, Department of Clinical and Biological Sciences, S. Luigi Hospital, Regione Gonzole 10, 10043, Orbassano Turin, Italy. daniela.cilloni@unito.it
Expert Opinion on Emerging Drugs
|March 6, 2010
Summary
Targeted therapy has revolutionized chronic myeloid leukemia (CML) treatment. This review covers tyrosine kinase inhibitors (TKIs), resistance, and emerging drugs for CML cure.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- BCR-ABL tyrosine kinase activity drives chronic myeloid leukemia (CML).
- Tyrosine kinase inhibitors (TKIs) transformed CML therapy, but resistance emerged.
- CML serves as a model for targeted molecular therapy development.
Purpose of the Study:
- To review clinical outcomes of imatinib and second-generation TKIs in CML.
- To summarize management guidelines for TKI-resistant CML.
- To describe novel drugs in development to overcome TKI resistance.
Main Methods:
- Literature review of clinical trials and guidelines.
- Analysis of TKI efficacy and resistance mechanisms.
- Exploration of preclinical and clinical drug development pipelines.
Main Results:
- TKIs have significantly improved CML patient outcomes.
- Clinical resistance to TKIs is a major challenge in CML management.
- New therapeutic strategies are being developed to address TKI resistance.
Conclusions:
- Targeted therapy, particularly TKIs, has dramatically altered CML treatment paradigms.
- Ongoing research focuses on novel drugs targeting pathways beyond BCR-ABL to enhance CML cure rates.
- Future CML management will likely involve combination therapies and agents overcoming resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...